Physician profile
Mark D Taber
NPI 1336100650
$2,111.29
in general payments reported to CMS, 2019-2025
25 companies · $98.09 in 2025
The $98.09 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $60.63 · 2021: $113 · 2022: $529 · 2023: $677 · 2024: $420 · 2025: $98.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $333.12 | 2020-2024 | Merlin@Home, Jot Dx |
| Novartis Pharmaceuticals Corporation | $283.24 | 2022-2025 | |
| Pfizer INC. | $228.62 | 2019-2025 | |
| Amgen INC. | $213.61 | 2019-2024 | Repatha |
| Abiomed | $164.00 | 2021-2023 | Impella |
| Cardiovascular Systems INC. | $151.53 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.99 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $82.39 | 2022-2024 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.64 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $66.20 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $59.62 | 2021-2023 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $52.80 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $46.43 | 2022-2023 | |
| Novo Nordisk INC | $42.62 | 2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $35.14 | 2023 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $30.89 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $25.36 | 2023 | Arcalyst |
| Ge Healthcare | $21.65 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.73 | 2022 | |
| Cvrx, INC. | $20.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.97 | 2024 | |
| Lantheus Medical Imaging, INC. | $18.65 | 2022 | |
| Scpharmaceuticals INC. | $17.06 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $14.56 | 2022 | |
| Biotronik INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Taber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.